Iradimed (IRMD) Q2 2026 earnings review
Product Transition Hits Margins and Growth; H2 Ramp Crucial
Iradimed faced a predicted 'trough' quarter as it transitions from its legacy 3860 IV pump to the new 3870 platform. Revenue flatlined at +0.5% YoY ($20.5M), while GAAP Net Income dropped 10%. The phase-out of the older model led to a severe 21.5% YoY contraction in pump revenue, dragging down overall growth. While management claims startup challenges were 'well managed,' Gross Margin compressed significantly by 400 basis points to 74%. Despite near-term pain, underlying demand metrics are highly encouraging: over 70% of new 3870 orders are for the high-ticket 'Quad stack' configuration, and domestic monitor bookings hit a record. Reaffirmed full-year guidance implies a massive, back-half-weighted acceleration.
🐂 Bull Case
Over 70% of new 3870 pump orders are for the four-pump 'Quad stack' configuration, effectively doubling the channel volume per customer and driving average deal sizes significantly higher.
The patient vital signs monitoring segment set a domestic booking record and grew revenue 12% YoY to $6.7M, providing crucial stability while the pump segment navigates its product transition.
🐻 Bear Case
Gross margin contracted from 78% in 25Q2 to 74% in 26Q2. The cost of ramping the 3870 production is weighing heavily on profitability, causing a 10% YoY drop in Net Income despite slightly higher sales.
To achieve the reaffirmed FY26 revenue midpoint of $93.5M, Iradimed must deliver over $51M in the second half—requiring a steep and flawless production ramp of the new 3870 platform.
⚖️ Verdict: ⚪
Neutral. The Q2 slowdown was heavily telegraphed, and the 'Quad stack' order mix is a powerful long-term tailwind. However, the 400 bps margin compression and the sheer steepness of the required H2 revenue ramp inject significant short-term execution risk.
Key Themes
3870 'Quad Stack' Exceeding Expectations
The 3870 MR IV pump launch is yielding a highly favorable product mix. Over 70% of new orders are for the 'Quad stack' configuration (four pumps on a single IV pole). This standardizes the hospital offering at double the typical channels of the legacy system, vastly increasing the ASP and long-term revenue potential from the installed base replacement cycle.
Resiliency in Monitors and Disposables
With the pump segment reversing to a 21.5% YoY decline during the transition, core recurring and secondary product lines stepped up. MRI Compatible Patient Vital Signs Monitoring systems grew 12% to $6.7M, and Disposables grew 14% to $4.8M. This diversification prevented total revenue from contracting sequentially.
Startup Inertia Crushes Gross Margins
Management stated that expected startup challenges for the 3870 were 'well managed by our manufacturing and engineering teams.' However, the data contradicts this optimistic tone: Gross Margin dropped drastically from 78% a year ago to 74% in 26Q2. This 400 bps compression indicates that manufacturing inefficiencies and unit cost scaling issues are currently bleeding the bottom line.
Steep Implied Q4 Revenue Ramp
Management reaffirmed FY26 revenue guidance of $91-$96M. With $42.4M banked in H1, and Q3 guided to a $23.75M midpoint, the implied Q4 revenue hurdle is roughly $27.3M. Moving from $20.5M in Q2 to $27.3M in Q4 requires flawless execution in manufacturing the 3870. Any supply chain hiccup will result in a full-year miss.
Operating Cash Flow Declines
Cash flow from operations decelerated sharply, falling 23% YoY to $5.9M in Q2. Management attributed this to lower net income and an increase in accounts receivable. As the company pre-builds inventory to support the massive H2 3870 ramp, working capital requirements will continue to heavily pressure free cash flow generation.
Other KPIs
Decelerating. Down from 78% in the comparable period of 2025. The company expects efficiencies to build as volumes scale, leading to a recovery in the second half of the year, but the initial margin penalty for the 3870 transition is severe.
Accelerating. Up 56% YoY from $0.48 million in 25Q2. While a small absolute contributor, this segment is showing consistent, rapid proportional growth as an add-on sale.
Guidance
Accelerating. The midpoint of $23.75M represents roughly a 12% YoY increase compared to Q3 2025's $21.2M, and a sharp sequential rebound from Q2's $20.5M, reflecting the expected volume build for the new 3870 pump.
Accelerating. The midpoint of $0.565 reflects sequential improvement from Q2's $0.46, indicating management's expectation that gross margins will immediately begin to recover as manufacturing efficiency scales.
Stable (Reaffirmed). The midpoint implies roughly 11.5% YoY growth over FY25. Given the flat Q2, maintaining this guidance requires an aggressive acceleration curve in Q3 and Q4.
Stable (Reaffirmed). Excludes $2.5 million of expected stock-based compensation expense for the full year.
Key Questions
Margin Recovery Visibility
Gross margin dropped to 74% this quarter due to 3870 startup inertia. What specific manufacturing KPIs give you confidence that you can return to historical 77-78% gross margins in the back half of the year?
Q4 Implied Ramp Risk
Maintaining full-year revenue guidance implies a massive leap to approximately $27 million in Q4. Is the supply chain completely derisked to handle a ~30% sequential volume jump from Q3 to Q4?
Quad Stack Pricing Dynamics
With over 70% of 3870 orders coming in as Quad stacks, are customers demanding volume discounts, or are you achieving your target 20% ASP uplift uniformly across these larger 4-channel deals?